How much does Mounjaro cost?

As of August 2026, Mounjaro self-pay costs a flat $499 a month at every approved strength — 2.5, 5, 7.5, 10, 12.5, and 15 mg all carry the same price, and it is available only through LillyDirect². Lilly's published list price is $1,112.16 per fill, where a fill means four pens¹. A commercially insured patient whose plan covers Mounjaro can pay as little as $25 for up to a three-month prescription³. The pricing structure is simpler than Zepbound's, but the coverage rules are not, and the reason is the label.

Mounjaro is the diabetes label of tirzepatide, and that decides everything downstream

Mounjaro and Zepbound are the same molecule under two separate FDA applications — Mounjaro is NDA 215866, Zepbound is NDA 217806, both Eli Lilly⁷. Mounjaro's labeled uses are blood sugar control in adults and children 10 and older with type 2 diabetes, and reducing the risk of major cardiovascular events in high-risk adults with type 2 diabetes⁸. Lilly's own site says it three times on a single page: "Mounjaro is not a weight loss drug"⁸. That distinction is not marketing hygiene. It is the reason a Mounjaro prescription and a Zepbound prescription meet completely different rules at a Part D plan, and the reason Mounjaro has no $299 tier and no Medicare $50 program.

The $499 is a direct channel price, not a pharmacy price

LillyDirect lists Mounjaro's single-dose prefilled pen at "Starting at $499/month" for all six strengths, tagged "For self-pay"². There is no Mounjaro vial and no Mounjaro KwikPen — one presentation, four pens to a month. Lilly's savings page states the channel plainly: "Mounjaro is available with prescription through LillyDirect (self-pay only) and other pharmacy options"³. Fulfillment runs through Amazon Pharmacy, Fuze Health, Gifthealth, or Walmart Pharmacy depending on your medicine and delivery choice, with home delivery or retail pickup². The price is also flagged as FSA/HSA eligible, subject to your plan².

Buying at $499 means signing a set of attestations, and one of them has a real cost consequence. You agree not to seek reimbursement from any insurance plan or government program for the purchase, and not to count what you paid toward a deductible or out-of-pocket requirement. If you are enrolled in Medicare Part D, you also agree that none of it counts toward your true out-of-pocket total⁴. So a Part D enrollee is not blocked from paying $499 — but that $499 does nothing to move them through their plan's spending phases. Compare it against your plan's actual cost-share before treating it as the cheap option.

Mounjaro landed on LillyDirect through Lilly's November 6, 2025 agreement with the federal government, which added Mounjaro, Trulicity, and Emgality "for self-pay patients with pricing 50-60% off their current list prices"⁹. Against a $1,112.16 list, $499 is a 55% reduction — squarely inside the announced band, and independently corroborated on the government's own price comparison site, which shows Mounjaro at $1,112.16 less $613.16 in savings¹⁰. The same release notes that the agreement "does not include pricing obligations in the commercial channel," which is why nothing about it changes what an insured patient pays.

What commercial insurance changes

With commercial drug insurance that covers Mounjaro, the savings card takes a one-, two-, or three-month single-dose pen prescription to "as little as $25" in total³. The card's own ceiling is what to check: up to $150 per one-month fill, $300 per two-month, $450 per three-month, and a separate annual maximum of $1,950 across up to 13 fills a year³. Those caps are meaningfully higher than the Zepbound card's $100 monthly and $1,300 annual limits, which is one of the few places where the diabetes label works in a patient's favor. If your plan leaves you owing more than the monthly cap, the card removes the cap amount and you pay the rest.

If your commercial plan does not cover Mounjaro, the card instead brings a one-month fill to "as low as $499," with savings capped at $647 monthly and $8,411 a year³. That lands at the same number as the LillyDirect self-pay price, through a different door. Card savings apply only to the six single-dose pen NDCs listed in the terms; other administration methods are excluded, and the published terms expire December 31, 2026³. Anyone enrolled in Medicaid, Medicare, Medicare Advantage, Medigap, DoD, VA, TRICARE, or a state pharmaceutical assistance program is ineligible for the card entirely³. Our insurance coverage guide covers the prior authorization and formulary steps that come before any of this.

Medicare treats Mounjaro better than Zepbound, and worse

Medicare's July 2026 GLP-1 program does not include Mounjaro, and that is by design rather than by omission. The Medicare GLP-1 Bridge, a CMS demonstration running July 1, 2026 through December 31, 2027, covers exactly three products at a $50 monthly copay: Foundayo, Wegovy, and the Zepbound KwikPen⁵⁶. It exists because weight-management use sits outside Part D — CMS built the Bridge to "operate outside of the Medicare Part D benefit's coverage and payment flow"⁵.

Mounjaro does not need that workaround. CMS states that "type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage," and that beneficiaries with those diagnoses "should continue to obtain their GLP-1 through their Part D plan"⁶. Medicare.gov puts the same rule from the patient side: you are not eligible for the Bridge if you have type 2 diabetes, "but your Part D plan might cover your GLP-1s"⁵. So a Mounjaro prescription is a normal Part D drug — coverable, but still subject to your plan's formulary, tier, and prior authorization, and to a copay or coinsurance that varies by plan. Lilly does not publish a typical figure; its pricing page says "Data on specific insurance plan pricing is not yet available"¹. For enrollees facing a large or lumpy Part D bill, Lilly points to the Medicare Prescription Payment Plan, a free federal tool that spreads plan-year drug costs into fixed monthly payments³.

Reading the list price

Lilly publishes Mounjaro's list price as a single number, $1,112.16 per fill, sourced to wholesale acquisition cost data accessed January 1, 2026, with a fill defined as four pens¹. Wholesale acquisition cost is what Lilly charges wholesalers, not what any patient is billed, and Lilly states that on the page¹. It is worth noting only because it is the number every downstream discount is measured against — and because it is higher than Zepbound's, which Lilly publishes as a $499 to $1,086.37 range. Same molecule, different application, different list. For the molecule-level view rather than the brand view, see how much tirzepatide costs, and for how brand pricing sits against the compounded market, see compounded vs brand-name GLP-1. Every figure here is Lilly's or the government's published price as of August 2026 and can change without notice; this is market context, not medical or financial advice.